(Q38233319)

31 August 2017

title

Cabozantinib: a review of its use in patients with medullary thyroid cancer (English)

1 reference

31 August 2017

Sheridan M Hoy

1

1 reference

31 August 2017

publication date

1 August 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

74

1 reference

31 August 2017

issue

12

1 reference

31 August 2017

page(s)

1435-1444

1 reference

Medullary thyroid cancer: therapeutic targets and molecular markers

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0265-X

Medullary thyroid carcinoma: molecular signaling pathways and emerging therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0265-X

2012 European thyroid association guidelines for metastatic medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0265-X

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0265-X

In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0265-X

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0265-X

The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0265-X

Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0265-X

Cabozantinib for the treatment of advanced medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0265-X

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0265-X

Cabozantinib in progressive medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0265-X

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0265-X

Mechanisms of adverse effects of anti-VEGF therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0265-X

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0265-X

Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25056653

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S40265-014-0265-X

1 reference

Dimensions Publication ID

31 August 2017

1052838888

0 references

1 reference